Sunshine Biopharma (SBFM) Stock Price, Quote & News

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: (954) 330-0684

Website: sunshinebiopharma.com

Address:

333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States

stockanalyzer777 Jul. 16 at 5:07 PM

$SBFM, $$GNS, $MLGO, $BNZI, $USEG $SBFM This stock needs a miracle to be revived. -$SBFM has HUGE upside potential. Current warrants are price at $15.38 per share -It has a low float. Share O 4.58 M, SF 4.55 M. target price is $15.00 per share. - SBFM has multiple catalyst scheduled to be released in the upcoming weeks/months. quarterly EARNING SCHEDULED FOR LATE JULY EARLY AUGUST -SBFM has 17 months of reserved funds. About Sunshine Biopharma Inc. Sunshine Biopharma currently has 72 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in the remainder of 2025. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

2 · Reply

contra7 Jul. 16 at 5:00 PM

$SBFM $SBFM This is exactly what’s been going on here for a while now IMO. The inflection point is imminent and the move up should be epic.

1 · Reply

stockanalyzer777 Jul. 16 at 3:08 PM

$GNS $SBFM $USEG

0 · Reply

DavidScott Jul. 16 at 3:33 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $HOLO $LIXT $SIDU $WWR $SBFM

0 · Reply

contra7 Jul. 15 at 5:27 PM

$SBFM A few weeks ago there were 400,000 shares available

0 · Reply

Nuisance Jul. 15 at 3:30 PM

$SBFM rocket starts ???

0 · Reply

BullDurham22 Jul. 15 at 11:32 AM

$SBFM This is my worst investment ever on paper, but this might change pretty soon

1 · Reply

stockanalyzer777 Jul. 14 at 8:18 PM

$SBFM Great investment !!!!!!! Sunshine Biopharma currently has 72 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in the remainder of 2025. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com. Warrants price between 15.38-$16.00 dollars $SBFM has a Nano float Insider owns: 0.08 % SO: 4.56 M SF: 4.55M Target Price: $15.00 per share $SBFM: The company has 17.9 months of cash left based on quarterly cash burn of -$1.71M and estimated current cash of $10.2M. https://dilutiontracker.com/app/search/SBFM https://finviz.com/quote.ashx?t=SBFM&p=d https://finance.yahoo.com/quote/SBFM/key-statistics/?p=SBFM

0 · Reply

Nuisance Jul. 13 at 5:49 PM

$SBFM https://www.newswire.ca/news-releases/nora-pharma-receives-health-canada-approval-for-niopeg-r-a-biosimilar-of-neulasta-r--883005213.html

1 · Reply

BigSqueezeComing Jul. 13 at 4:05 AM

$SBFM Earning is July 30. Expecting EPS -.11 and rev 11.2M to be reported. These number represent an increase from last earning report. Q2 earnings (expected July 30) likely to include first revenue from NIOPEG®, potentially boosting growth further. Likely to include early sales data for both everolimus and gabapentin—but these may still be modest and aggregated.

1 · Reply

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jun 11, 2025, 8:30 AM EDT - 5 weeks ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

May 15, 2025, 4:15 PM EDT - 2 months ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 6, 2025, 8:30 AM EDT - 2 months ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Apr 21, 2025, 8:30 AM EDT - 3 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 3, 2025, 10:50 AM EDT - 3 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 2, 2025, 1:20 PM EDT - 3 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 11:35 AM EDT - 3 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 1, 2025, 5:09 PM EDT - 3 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 10, 2025, 9:00 AM EDT - 4 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Jan 21, 2025, 8:00 AM EST - 6 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 15, 2025, 8:00 AM EST - 6 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Dec 9, 2024, 7:30 AM EST - 7 months ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 4, 2024, 4:05 PM EST - 8 months ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 2, 2024, 8:00 AM EST - 8 months ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Nov 6, 2024, 8:00 AM EST - 9 months ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sep 26, 2024, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 4, 2024, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Aug 26, 2024, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 19, 2024, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Feb 15, 2024, 9:15 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Dec 4, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Moves Principal Office to New York City

Nov 13, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sep 21, 2023, 9:05 PM EDT - 1 year ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 10, 2023, 7:35 AM EST - 2 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Jan 19, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Announces Share Repurchase Program

Dec 20, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma's Annual Letter to Shareholders

Dec 5, 2022, 5:46 PM EST - 2 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Nov 16, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Oct 20, 2022, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Jul 28, 2022, 8:10 AM EDT - 3 years ago

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

May 9, 2022, 11:03 AM EDT - 3 years ago

Sunshine Biopharma: An Opportunity Knocking?

Apr 28, 2022, 4:50 PM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 28, 2022, 9:20 AM EDT - 3 years ago

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Apr 26, 2022, 12:41 AM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 25, 2022, 10:57 AM EDT - 3 years ago

Why Sunshine Biopharma Stock Is Surging

stockanalyzer777 Jul. 16 at 5:07 PM

2 · Reply

contra7 Jul. 16 at 5:00 PM

$SBFM $SBFM This is exactly what’s been going on here for a while now IMO. The inflection point is imminent and the move up should be epic.

1 · Reply

stockanalyzer777 Jul. 16 at 3:08 PM

$GNS $SBFM $USEG

0 · Reply

DavidScott Jul. 16 at 3:33 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $HOLO $LIXT $SIDU $WWR $SBFM

0 · Reply

contra7 Jul. 15 at 5:27 PM

$SBFM A few weeks ago there were 400,000 shares available

0 · Reply

Nuisance Jul. 15 at 3:30 PM

$SBFM rocket starts ???

0 · Reply

BullDurham22 Jul. 15 at 11:32 AM

$SBFM This is my worst investment ever on paper, but this might change pretty soon

1 · Reply

stockanalyzer777 Jul. 14 at 8:18 PM

0 · Reply

Nuisance Jul. 13 at 5:49 PM

$SBFM https://www.newswire.ca/news-releases/nora-pharma-receives-health-canada-approval-for-niopeg-r-a-biosimilar-of-neulasta-r--883005213.html

1 · Reply

BigSqueezeComing Jul. 13 at 4:05 AM

1 · Reply

Bat_shtt_crazy Jul. 11 at 9:27 PM

$SBFM https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2025 Going to be a hell of a year in 2026 for us!

1 · Reply

Bat_shtt_crazy Jul. 11 at 9:23 PM

$SBFM The patient for Entresto is up July 15th. In 2024 Novartis sales were 7.8 Billion for this exclusive drug. This will be our next leg up. This is going to hurt shorty. My guess we see this PR soon! https://www.fiercepharma.com/pharma/novartis-presses-court-hasty-decision-long-running-entresto-patent-feud-msn

0 · Reply

MB66 Jul. 11 at 6:45 PM

$SBFM https://mailchi.mp/norapharma/linfolettre-nora-pharma-14195667?e=cde766ea42

0 · Reply

stockanalyzer777 Jul. 11 at 6:26 PM

$SBFM Seeking alpha has $SBFM earning scheduled for July 30, 2025. I hope we can get a catalyst next week and start this multi-day/week run. In the mean time please post a blog about $SBFM over the weekend. It's a great investment. FYI, warrants were issued in Jan for target price of $15.00.

0 · Reply

BullDurham22 Jul. 11 at 3:06 PM

$SBFM It would be great to hear the CEO support his shareholders

0 · Reply

contra7 Jul. 10 at 7:35 PM

$SBFM This barcoding price action looks like the calm before the storm. This thing is way overdue for a serious run, LFG!!!

0 · Reply

Nuisance Jul. 10 at 7:09 PM

$SBFM

0 · Reply

stockanalyzer777 Jul. 10 at 4:29 PM

$SBFM $PCSA $GNS $USEG

0 · Reply

Love_To_Learn Jul. 9 at 11:15 PM

$SBFM ill need to remove a few volume absorbers from your grid for tomo b4 close as well u r few days behind on movement cycle

1 · Reply

Love_To_Learn Jul. 9 at 10:16 PM

$SYBX $SBFM making changes for u both

1 · Reply

stockanalyzer777 Jul. 9 at 5:21 PM

$SBFM $GNS Let's Go!!!!!!!

0 · Reply

MB66 Jul. 9 at 4:40 PM

$SBFM @Bat_shtt_crazy i noticed some warrants being offered at $13, so I went ahead and offered some at $15. Let’s get there, brotha!! 💪

1 · Reply

Market Cap	6.87M
Revenue (ttm)	34.87M
Net Income (ttm)	-5.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14.71%
Debt to Equity Ratio	0.00

Volume	49,938
Avg Vol	143,194
Day's Range	N/A - N/A
Shares Out	4.56M
Stochastic %K	43%
Beta	1.44
Analysts	Strong Sell
Price Target	$7.00